EBV related cerebral lymphoma in a leukemia patient treated with alemtuzumab.
B
B
van de Langerijt
J K
JK
Doorduijn
K H
KH
Lam
M J
MJ
van den Bent
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001932:Brain Neoplasms / Q000473:pathology / Q000821:virology*; D003520:Cyclophosphamide / Q000627:therapeutic use; D020031:Epstein-Barr Virus Infections / Q000150:complications* / Q000473:pathology; D004854:Herpesvirus 4, Human; D006801:Humans; D007107:Immune System / Q000187:drug effects; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000473:pathology / Q000821:virology*; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000473:pathology / Q000821:virology*; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine